期刊文献+

肝癌高危人群的保护性研究 被引量:3

Protective research of high-risk population of hepatocellular carcinoma
暂未订购
导出
摘要 目的 :探索有效、安全、价廉的药物 ,以尽可能减少肝癌高发区高危人群的肝癌发生率以及降低肝癌根治性切除后的复发率。方法 :对高危人群 3 91例及术后患者 189例分别分成实验组和对照组。实验组服用纯中药制剂软坚护肝片加甘草甜素片 ,对照组应用一般护肝药。治疗 3年以上 ,长期追踪。结果 :高危人群实验组肝癌发生率 0 72 % ,对照组为 9 9% ,两组比较差异有统计学意义 ,P <0 0 1;术后人群实验组肝癌 3、5年复发率分别为 11 69%和 15 5 8% ,明显低于对照组的 3 0 3 6%和 3 9 2 9% ,P <0 0 5。结论 :软坚护肝片和甘草甜素片对长期暴露于较强肝癌危险因素的人群有良好的保护作用。 OBJECTIVE:To probe into the effective, safe and economical medicine to reduce the incidence of hepatocellular carcinoma(HCC)among high-risk population and the recurrence of patients who underwent radical resection. METHODS: A total of 319 high-risk people and 189 operated patients of HCC were divided into test group and control group respectively. Test group had pure Chinese medicine Ruan Jian Hu Gan Pian and Ga Cao Tian Su Pian for more than 3 years, while the control group had ordinary hepatic medicine. All of them were long-term followed.RESULTS: Among the high-risk people, the incidence of HCC in test group was 0.72% while the rate in control group 9.9%,P<0.01. Among the operated patients, 3- and 5-year recurrences were 11.69% and 15.11% in test group, which were statistically inferior to those in control group with 30.36% and 39.29 respectively, P<0.05. CONCLUSION: Ruan Jian Hu Gan Pian combined with Ga Cao Tian Su Pian has the advantage to protect the high-risk population of HCC.
出处 《肿瘤防治杂志》 2004年第9期907-909,共3页 China Journal of Cancer Prevention and Treatment
关键词 肝肿瘤/预防和控制 肝炎 乙型 肝肿瘤/中药疗法 发病率 liver neoplasms/prevention & control hepatitis B liver neoplasms/drug therapy incidence rate
  • 相关文献

参考文献9

二级参考文献34

共引文献176

同被引文献38

  • 1拉米夫定临床应用专家组,万谟彬.2004年拉米夫定临床应用专家共识[J].中华传染病杂志,2004,22(4):283-287. 被引量:88
  • 2梁水庭,覃晓,黎乐群,陆云飞,覃忠,林进令,巫山,梁雪婧,周惠森.软坚护肝片及甘草甜素片对肝癌术后复发的干预性研究[J].临床肝胆病杂志,2004,20(5):293-294. 被引量:11
  • 3郭庆渠,梁水庭,梁雪婧,余辉.软坚护肝片预防肝纤维化形成的实验研究[J].广西医科大学学报,2007,24(2):261-263. 被引量:10
  • 4梁水庭,巫山,林进令,黎乐群,陆云飞,廖清华,苏翼联.软坚护肝片的护肝及抗乙肝病毒作用的实验研究——附74例乙肝病毒携带者疗效观察[J].中医药研究,1997,13(3):50-54. 被引量:10
  • 5E1-Serag HB,Rudolph KL. Hepatocellular carcinoma:epidemiol- ogy and molecular carcinogenesis. Gastroenterology,2007,132: 2557-2576.
  • 6Lok ASF,McMahon BJ. Chronic hepatitis B. Hepatology,2007,45 : 507-539.
  • 7Papatheodoridis GV,Manolakopoulos S,Dusheiko G,et al. Thera- peutic strategies in the management of patients with chronic hepatitis B. Lancet Infect Dis,2008,8:167-178.
  • 8Papatheodoridis GV,Dimou E,Dimakopoulos K,et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long- term nucleos(t)ide analog therapy starting with lamivudine. Hep- atology, 2005,42 : 121-129.
  • 9Papatheodoridis GV,Manolakopoulos S. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral starting with lamivudine monotherapy: results of the nationwide HEPNET/Greeee Cohort Study. Gut, 2011,60:1109-1116.
  • 10Sehafer DF,Sorrell MF. Hepatoeellular carcinoma. Lancet, 1999, 353 : 1253-1257.

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部